The landscape of breast cancer treatment is currently undergoing a paradigm shift, moving away from "one-size-fits-all" chemotherapy protocols toward a more nuanced, biomarker-driven approach. Recognizing the critical need for consistency and innovation in this field, Taylor & Francis has officially announced a new, dedicated Article Collection titled "Breast cancer biomarkers in diagnostic and translational pathology." Hosted by the peer-reviewed journal Breast Cancer: Targets and Therapy, this initiative seeks to bridge the gap between bench-side molecular discovery and bedside clinical application.
As diagnostic pathology becomes increasingly sophisticated, the ability to standardize biomarker testing has emerged as a cornerstone of patient safety and treatment efficacy. By inviting researchers to contribute their findings, Taylor & Francis aims to synthesize the latest global research on immunohistochemical and molecular testing to refine routine diagnostic practices.
Main Facts: The Scope and Objective
The primary objective of this Article Collection is to address the persistent challenges regarding the reproducibility and standardization of breast cancer biomarker testing. While molecular pathology has advanced significantly, the integration of these high-tech diagnostics into routine clinical practice remains inconsistent across global healthcare systems.
The collection will curate research that explores:
- Methodological Optimization: Novel strategies to enhance the sensitivity and specificity of current immunohistochemical assays.
- Translational Hurdles: Research detailing the journey of a biomarker from initial discovery in a laboratory setting to its validation and implementation in pathology departments.
- Standardization Protocols: Proposals for universal reporting standards to ensure that patients receive consistent diagnostic interpretations regardless of where they are tested.
- Molecular Signatures: Analysis of emerging biomarkers that may predict resistance to endocrine therapies or sensitivity to novel targeted agents.
The initiative emphasizes that all submissions will undergo a rigorous, independent peer-review process, ensuring that only the most robust, high-quality data reaches the publication stage. To maintain the integrity of the peer-review process, the designated Guest Advisor will not be involved in the evaluation of individual manuscripts, unless they are serving in an existing Editorial Board capacity.
Chronology: The Timeline for Global Submission
The timeline for this initiative has been designed to allow for extensive laboratory research and data compilation. Taylor & Francis has set the official deadline for submissions for December 31, 2026.
- Announcement Phase (Current): The call for papers is now open, and the academic community is invited to prepare manuscripts that align with the journal’s scope.
- Submission Window (Ongoing): Researchers are encouraged to review the journal’s submission guidelines carefully. Authors must select the specific "Article Collection" drop-down menu option within the online portal to ensure their work is categorized correctly.
- Peer-Review Cycle: Manuscripts submitted throughout the window will undergo iterative review. Accepted articles will be published as they are finalized, contributing to the collection in real-time.
- Final Deadline (December 31, 2026): All final submissions must be uploaded by the close of the calendar year 2026 to be considered for inclusion in this specific collection.
Supporting Data: Why Biomarkers Matter
Breast cancer remains the most frequently diagnosed cancer among women globally. According to recent clinical data, the prognosis for breast cancer patients is inextricably linked to the early and accurate identification of molecular biomarkers such as Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2).
However, data suggests that up to 15–20% of cases may suffer from "discordant results" due to variations in tissue fixation, staining protocols, and subjective interpretation. By focusing on "translational pathology," this collection aims to reduce this margin of error.
Furthermore, the emergence of liquid biopsies—the detection of circulating tumor DNA (ctDNA) and tumor-derived extracellular vesicles—represents a frontier in biomarker research. This collection provides a platform for researchers to present longitudinal data on how these less invasive methods can complement traditional tissue biopsies, potentially allowing for real-time monitoring of tumor evolution and treatment resistance.
Official Responses and Editorial Guidance
The editorial team at Breast Cancer: Targets and Therapy emphasizes that while the collection has a specific focus, the submission criteria remain stringent. Authors are urged to review the journal scope and the author submission instructions before beginning their draft.
Rebecca Turner, serving as the primary point of contact for this collection, has invited inquiries from prospective authors. Researchers who require clarification on thematic fit, or those seeking information regarding potential discount codes for open access publication, are encouraged to contact her via email. The publisher maintains that financial barriers should not prevent significant scientific breakthroughs from being shared with the global community, and the availability of these codes is part of their commitment to equitable access.
Implications: The Future of Precision Pathology
The implications of this Article Collection extend far beyond the pages of an academic journal. By centralizing the discourse on biomarker standardization, Taylor & Francis is facilitating a global conversation that could directly influence the development of international clinical guidelines.
1. Enhancing Patient Outcomes
Standardization is the bedrock of patient safety. When biomarker testing is reproducible, oncologists can make treatment decisions with confidence. This reduces the risk of over-treatment or under-treatment, both of which have profound psychological and physical consequences for patients.
2. Driving Technological Innovation
The call for papers encourages the submission of work regarding digital pathology and AI-assisted image analysis. As pathology departments increasingly integrate artificial intelligence to score immunohistochemical slides, this collection will serve as a repository for the validation studies necessary to approve these technologies for clinical use.
3. Fostering International Collaboration
By providing a unified platform, the collection invites researchers from diverse socioeconomic backgrounds to share their data. This is particularly vital in the context of global health, where resource-limited settings may have different diagnostic challenges compared to high-resource centers. Sharing these varied perspectives helps in designing more resilient, universally applicable diagnostic frameworks.
4. Supporting Translational Research
Translational pathology is the vital link between identifying a molecule and saving a life. By focusing on the "translation" of these markers, the journal ensures that high-impact discoveries do not remain locked in research silos but are instead moved into the hands of clinical pathologists who can apply them to daily patient care.
Conclusion
The upcoming collection in Breast Cancer: Targets and Therapy stands as a testament to the evolving nature of cancer research. As we head toward 2026, the scientific community is presented with a unique opportunity to contribute to a seminal body of work that addresses the most critical technical challenges in modern oncology.
For researchers, clinicians, and pathologists, this is an invitation to define the next era of diagnostic excellence. Whether it is through refining existing protocols or exploring the frontier of molecular diagnostics, the submissions gathered in this collection will undoubtedly play a pivotal role in shaping how breast cancer is identified, classified, and treated for years to come.
For further information, authors are encouraged to visit the official Article Collection page. Through collaboration, rigorous peer review, and a focus on clinical utility, the goal of a fully standardized, highly accurate approach to breast cancer diagnosis is well within reach.
About the Author
